|
|
1.
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. MedStar authors:
Year: 2013
Citation: - Journal of the National Cancer Institute. 105(23):1782-8, 2013 Dec 4.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Bandos H, Blackmon NL, Bohn OL, Burandt E, Costantino JP, Fehrenbacher L, Fumagalli D, Gavin PG, Geyer CE Jr, Goldstein LC, Horne ZD, Jeong JH, Kim C, Kim SI, Kim SR, Lee A, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Reilly ML, Remillard MY, Romond EH, Sneige N, Swain SM, Tanaka N, Taniyama Y, Wickerham DL, Wolmark N
|
|
|
2.
|
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Oncology. 33(12):1340-7, 2015 Apr 20.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Blackmon NL, Costantino JP, Fehrenbacher L, Finnigan M, Gavin PG, Geyer CE Jr, Jeong JH, Kim SR, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Song N, Swain SM, Wickerham DL, Wolmark N
|
